All In Biotech

Drug Trial Radar · NCT04669067

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)

Last checked: Nov 19, 2026Latest source record: Feb 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

18

Actual

Start

Mar 31, 2021

Primary completion

Nov 2024

Study completion Nov 2025

Sponsor

Lead sponsor
Telios Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Kartos Therapeutics, Inc.
First posted
Dec 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with navtemadlin (KRT-232), a novel oral small molecule inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed prior therapy) to be eligible for this study.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • TL-895Drug

    TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

  • KRT-232Drug

    KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Objective, Phase 1b: To determine the MTD/MAD and recommended Phase 2 dose (RP2D) of TL-895 in combination with KRT-232Time frame: 13 months
  2. Primary Objective, Phase 2: To determine the rates of complete remission (CR) and complete remission with partial hematologic recovery (CRh)Time frame: 41 months

Locations

35 sites in 8 countries. Site status is shown where the registry gives one.

  • Keck School of Medicine

    Los Angeles, California

  • University of California, Irvine Medical Center

    Orange, California

  • Georgia Cancer Center

    Augusta, Georgia

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Rush University Medical Center, Division of Hematology Oncology and Cell Therapy

    Chicago, Illinois

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Weill Cornell Medical College

    New York, New York

  • University of Cincinnati

    Cincinnati, Ohio

  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization

    Philadelphia, Pennsylvania

  • UT Southwestern Medical Center, Harold C. Simmons Cancer Center

    Dallas, Texas

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • University of Sunshine Coast-Sippy Downs

    Sippy Downs, Australia

  • Westmead Hospital

    Sydney, Australia

  • Ordensklinikum Linz GmbH Elisabethinen

    Linz, Austria

  • Medical University Vienna, Department of Internal Medicine I, Clinical Department of Hematology and Hemostaseology

    Vienna, Austria

  • Claude Huriez Hospital

    Lille, France

  • South Lyon Hospital Center

    Lyon, France

  • Paoli-Calmettes Institute

    Marseille, France

  • University Hospital of Nantes

    Nantes, France

  • Hospital Center Universitaire De Nice

    Nice, France

  • Saint-Louis Hospital

    Paris, France

  • University Duisburg-Essen, University Hospital Essen, Department of Internal Medicine

    Essen, Germany

  • University Hospital Hamburg-Eppendorf, Department of Internal Medicine II

    Hamburg, Germany

  • Hannover Medical School, Center for Internal Medicine, Clinic of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation

    Hanover, Germany

  • University Hospital Jena, Clinic of Internal Medicine II, Department of Hematology and Medical Oncology

    Jena, Germany

  • University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology

    Halle, Saxony-Anhalt, Germany

  • University Hospital - Ospedali Riuniti Umberto I - GM Lancisi - G Salesi of Ancona, Haematology Clinic

    Ancona, Italy

  • Polyclinic S. Orsola-Malpighi, Operative Unit of Hematology

    Bologna, Italy

  • Romagnolo Scientific Institute of Meldola (IRST) S.r.l., Department of Oncology and Clinical and Experimental Haematology

    Meldola, Italy

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Seoul National University Hospital, Department of Hemato-Oncology

    Seoul, South Korea

  • University Hospital Germans Trias i Pujol, Department of Clinical Hematology

    Badalona, Spain

  • University Hospital Vall d'Hebron

    Barcelona, Spain

  • University Clinical Hospital of Valencia, Department of Hematology and Medical Oncology

    Valencia, Spain

  • Hospital Universitario y Politécnico de La Fe

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.